Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.
LYMErix (SmithKline Beecham): Full Drug Profile
Medically reviewed by Dr. Otari Nergadze, Neurosurgeon | Updated: January 2026
LYMErix (SmithKline Beecham) - General Information
Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant.
Pharmacology of LYMErix (SmithKline Beecham)
LYMErix (SmithKline Beecham) is a single polypeptide chain of 270 amino acids. It is a vaccination used to prevent Lyme Disease.
Additional information about LYMErix (SmithKline Beecham)
- LYMErix (SmithKline Beecham) Indication
For prophylactic treatment of Lyme Disease
- Mechanism Of Action
- LYMErix (SmithKline Beecham), an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, is used to stimulate the production of specific antibodies against B. burgdorferi. B. burgdorferi. Therefore, it is used as a vaccination against Lyme Disease.s
- Generic Name
- OspA lipoprotein
- Synonyms
- Outer surface protein A precursor
- Drug Category
- Vaccines
- Drug Type
- Biotech; Approved
- Other Brand Names containing OspA lipoprotein
- LYMErix (SmithKline Beecham);
- Half Life
- 1.2 hours (mammalian reticulocytes, in vitro).
- Chemical IUPAC Name
- Borrelia outer surface protein A (OspA)
- Chemical Formula
- C1198H2012N322O422S2
- Organisms Affected
- Humans and other mammals